UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 1473-1
Program Prior Authorization/Notification
Medication Hympavzi™ (marstacimab-hncq)
P&T Approval Date 3/2025
Effective Date 7/1/2025
1. Background:
Hympavzi (marstacimab-hncq) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for
routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric
patients 12 years of age and older with:
• hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors
• hemophilia B (congenital factor IX deficiency) without factor IX inhibitors
2. Coverage Criteriaa:
A. Hemophilia A Without Inhibitors
1. Initial Authorization
a. Hympavzi will be approved based on all of the following criteria
1) Diagnosis of hemophilia A
-AND-
2) Patient is 12 years of age or older
-AND-
3) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
-AND-
4) Patient does not have a history of inhibitors to factor VIII
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Documentation of positive clinical response to Hympavzi therapy
Authorization will be issued for 12 months.
B. Hemophilia B Without Inhibitors
1. Initial Authorization
© 2025 UnitedHealthcare Services Inc.
1
a. Hympavzi will be approved based on all of the following criteria
1) Diagnosis of hemophilia B
-AND-
2) Patient is 12 years of age or older
-AND-
3) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
-AND-
4) Patient does not have a history of inhibitors to factor IX
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Documentation of positive clinical response to Hympavzi therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim
logic. Use of automated approval and re-approval processes varies by program and/or
therapeutic class.
• Medical Necessity may be in place.
4. References:
1. Hympavzi™ [package insert]. New York, NY: Pfizer Inc., October 2024.
Program Prior Authorization/Notification - Hympavzi (marstacimab-hncq)
Change Control
3/2025 New program.
© 2025 UnitedHealthcare Services Inc.
2